The short version of melanocortin receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or below | For the lyophilised powder, desiccated |
| Storage form | Sealed vial, protected from light | Amber glass or foil-wrapped containers |
| Reconstituted stability | Short, refrigerate | Degradation accelerates in solution |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity assessment plus identity confirmation |
| Common synonyms | Melanotan II, MT-II | Also written melanotan-2 |
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
The precise direct molecular mechanism of action by which bromantane ultimately acts as a dopamine synthesis enhancer is unknown. However, it has been determined that activation of certain cAMP-, Ca2+-, and phospholipid-dependent protein kinases such as protein kinase A and especially protein kinase C corresponds with the manifestation of the pharmacological effects of bromantane. Bromantane may activate intracellular signaling cascades by some mechanism (e.g., agonizing some as-yet-undetermined receptor) to in turn activate protein kinases, which in turn cause increased transcription of TH and AAAD. The related drugs amantadine and memantine also have many properties similar to those of bromantane. Researchers discovered that amantadine and memantine bind to and act as agonists of the σ1 receptor (Ki = 7.44 μM and 2.60 μM, respectively) and that activation of the σ1 receptor is involved in the central dopaminergic effects of amantadine at therapeutically relevant concentrations; the authors of the study stated that this could also be the mechanism of action of bromantane, as it is in the same family of structurally related compounds and evidence suggests a role of dopamine in its effects. But this could also be seen as evidence of the contrary since bromantane has effects that are distinctly different from amantadine and memantine.
== Radionuclides == When radionuclides are used pharmacologically, for example in radiation therapy, they are eliminated through a combination of radioactive decay and biological excretion. An effective half-life of the drug will involve a decay constant that represents the sum of the biological and physical decay constants, as in the formula:
It was not proven that the testes released a substance that engenders male characteristics until it was shown that the extract of testes could replace their function in castrated animals. Pure, crystalline testosterone was isolated in 1935. Graves' disease was named after Irish doctor Robert James Graves, who described a case of goiter with exophthalmos in 1835. The German Karl Adolph von Basedow also independently reported the same constellation of symptoms in 1840, while earlier reports of the disease were also published by the Italians Giuseppe Flajani and Antonio Giuseppe Testa, in 1802 and 1810 respectively, and by the English physician Caleb Hillier Parry (a friend of Edward Jenner) in the late 18th century. Thomas Addison was first to describe Addison's disease in 1849.
In 1924, Hahn was elected to full membership of the Prussian Academy of Sciences in Berlin, by a vote of thirty white balls to two black. While still remaining the head of his own department, he became Deputy Director of the KWIC in 1924, and succeeded Alfred Stock as the director in 1928. Meitner became the director of the Physical Radioactivity Division, while Hahn headed the Chemical Radioactivity Division. In the early 1920s, Hahn created a new line of research. Using the "emanation method", which he had recently developed, and the "emanation ability", he founded what became known as "applied radiochemistry" for the researching of general chemical and physical-chemical questions. In 1936 Cornell University Press published a book in English (and later in Russian) titled Applied Radiochemistry, which contained the lectures given by Hahn when he was a visiting professor at Cornell University in Ithaca, New York, in 1933. This publication had a major influence on almost all nuclear chemists and physicists in the United States, the United Kingdom, France, and the Soviet Union during the 1930s and 1940s. Hahn is referred to as the father of nuclear chemistry, which emerged from applied radiochemistry.
Union of Sovereign States: The treaty proposed to set up a Union of Sovereign and Equal States based on democracy and rule-of-law as successor to the Union of Soviet Socialist Republics. This new polity was envisioned as a voluntary association of sovereign republics with a common federal government. A member joins the Union either directly or as a part of other states, and relations between members when one of them is a part of another are regulated by treaties between them. Presidential Council: The treaty proposed the creation of a Presidential Council that would consist of the leaders of the republics and the president of the Union. This council would be responsible for making important decisions and coordinating policies at federal level. A Union Constitutional Court would be created to settle disputes over questions of the exercise of the powers of Union organs. The legislative power of the Union would be exercised by the USSR Supreme Soviet, which consists of two chambers: the Soviet of the Republics, elected by the population of the whole country, and the Soviet of the Union. Decentralization of Power: The treaty aimed to decentralize political power by granting greater autonomy to the Republics giving them general guarantees about the right to control their own resources and legislate including the right to freely secede from the Union. Division of Powers: The central government would handle issues of defence, foreign affairs, financial system, energy resources and overall coordination along with issuing its currency.
Sources: en.wikipedia.org
Computer-based methods for predicting the binding orientation and affinity of an inhibitor for an enzyme such as molecular docking and molecular mechanics can be used to assist in the optimisation process. New inhibitors are used to obtain crystallographic structures of the enzyme in an inhibitor/enzyme complex to show how the molecule is binding to the active site, allowing changes to be made to the inhibitor to optimise binding in a process known as structure-based drug design. This test and improve cycle is repeated until a sufficiently potent inhibitor is produced.
He further dismissed India's firm stance on pursuing terrorists as a “new abnormal,” stating it did not serve the interests of either country. Bilawal Zardari faced strong criticism from the Pakistan Tehreek-e-Insaf (PTI) following his remarks suggesting that Pakistan could extradite “individuals of concern” to India as a confidence-building measure. PTI Central Information Secretary Sheikh Waqas Akram condemned the statement as undermining national security and appeasing a "hostile neighbour", calling him an “immature political child” and accusing him of lacking understanding of regional geopolitics. Akram argued that such proposals compromised Pakistan’s sovereignty and contradicted the legacy of the Pakistan Peoples Party, particularly on the Kashmir issue. He further criticized Bilawal Zardari’s political credibility and called for a leadership change within the party. Talha Saeed, son of Hafiz Saeed, condemned Bilawal Zardari remarks on the possible extradition of Pakistani citizens to India, calling them contrary to state policy and national interest, and defended his father by asserting that none of his actions were against Pakistan.
On Thursday, February 1, 1866, Mary Baker Eddy, then known as Mary Patterson, fell on the ice in Lynn, Massachusetts. She had been on the way to a Good Templars meeting, an organization supporting the temperance movement, with friends from the organization. After her fall, the Lynn Reporter wrote that she was "in an insensible condition" and had internal injuries, and the notes of Dr. Alvin M. Cushing, a homeopathic doctor, who was called to the scene, state that he found Eddy "partially unconscious, semi-hysterical and complaining by word and action of severe pain in the back of her head and neck." She was taken to the nearest house, that of Samuel M. Bubier the future mayor of Lynn, and spent the night there. Cushing attended to her multiple times that day and during the night, which Gill writes "indicates that he considered the accident serious," and he gave orders that homeopathic medicine be continually given her at intervals of every half hour when she was awake while he was not present. Cushing later told Sibyl Wilbur that Eddy "was taken up unconscious and remained unconscious during the night" and that he thought she was "suffering from a concussion, and possible spinal dislocation." The next morning Eddy asked to be taken to her home in Swampscott, which Cushing arranged for against his own professional advice. In order to dull the pain of moving, Cushing gave Eddy "one-eighth of a grain of morphine" (a common painkiller at the time) according to his notes from the period.
=== Leon Carp === Leon Carp is played by Martin Mull. Leon, originally as Roseanne's boss at Rodbell's Luncheonette and later as her business partner in The Lanford Lunchbox, he is portrayed as a foe to Roseanne; although they have a contentious relationship at times, Leon gradually becomes a close friend of the Conners, ultimately becoming a surrogate family member. As a gay man, he is occasionally seen dating many men and having romantic troubles; however, he later marries his life partner Scott (Fred Willard) in a very public ceremony. In the ninth season, they visit the Conner residence bearing gifts for Darlene and David's new baby, Harris, proclaiming themselves as the infant's Aunt Scott and Aunt Leon. Near the end of the episode, they announce their plans to adopt a little girl. Leon's role in the series expands significantly in the eighth and ninth seasons, as he is featured in more episodes. He is especially upset when Roseanne wins the lottery, but Roseanne and Jackie end up relinquishing control of the restaurant to Leon and Nancy. Leon is a Republican, and holds George Bush in high regard. He also is shown throughout the series' run to be a fan of Liza Minnelli, as well as Broadway musicals. Leon did not appear in season 10, nor did he appear on the spin-off series.
The Gallery of Palaeontology and Comparative Anatomy was built between 1894 and 1897 by architect Ferdinand Dutert, who had built the innovative iron-framed Galerie des machines at the 1889 Paris Exposition. A new pavilion in the same style was added to the west side of the gallery; it was completed in 1961. In front of the Gallery is the Iris Garden, created in 1964, which displays 260 varieties of iris flowers, and a sculpture, "Nymph with a pitcher" (1837) by Isidore Hippolyte Brion. The sides of gallery are also decorated with sculpture; twelve relief sculptures of animals in bronze and fourteen medallions of famous biologists. The ironwork grill and stone arches over the entrance are filled with elaborate designs and sculpture of seashells. Inside the entrance is a large marble statue of an Orangutan strangling a hunter, created in 1885 by the noted animal sculptor Emmanuel Fremiet, best known for his statue of Joan of Arc on horseback on the Place des Pyramides in Paris.
Sources: en.wikipedia.org
The lyophilised solid is best kept cold, dry and dark, typically at minus twenty degrees Celsius. Moisture and repeated warming cycles are the main causes of degradation. Solutions prepared from the powder are less stable and are normally used quickly.
Reversed-phase liquid chromatography assesses purity, while mass spectrometry confirms molecular mass and detects sequence errors. Amino acid analysis and peptide mapping add structural detail. These techniques are complementary rather than interchangeable.
It is listed as a prohibited peptide hormone by the World Anti-Doping Agency. No medicines regulator has approved it for human use. Import and sale rules vary by country.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.